Assessment of chemosensitivity by monitoring bcl-2 transcript kinetics in acute myeloid leukemias.
Enforced bcl-2 gene expression suppresses apoptosis and confers resistance to anticancer drugs. Here we established a real time fluorescence PCR assay to analyze the association between the bcl-2 gene expression and clinical chemosensitivity in acute myeloid leukemia. Expression levels of the bcl-2 gene were measured and normalized by beta-actin, a housekeeping gene expressed as endogenous reference. By applying real time PCR to clinical samples, we observed that although the bcl-2/beta-actin ratio was not related to FAB subtypes, the changing data following remission induction therapy clearly reflected drug-sensitivity. These results suggest that RT-PCR assay monitored the efficacy of the chemotherapy by quantifying the bcl-2 gene transcript in AML.
Liu
Kaishan
K
Department of Pathology, Medical College, Jinan University, Guangzhou, Guangdong 510632, China. tlksh@jnu.edu.cn
Kreuzer
Karl-Anton
KA
Lass
Ulrich
U
Schmidt
Christian Andreas
CA
D000208:Acute Disease; D016022:Case-Control Studies; D016903:Drug Monitoring / Q000379:methods*; D006801:Humans; D007700:Kinetics; D007951:Leukemia, Myeloid / Q000175:diagnosis* / Q000188:drug therapy; D018365:Neoplasm, Residual / Q000175:diagnosis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics*; D012333:RNA, Messenger / Q000032:analysis; D011933:Reagent Kits, Diagnostic; D012074:Remission Induction; D020133:Reverse Transcriptase Polymerase Chain Reaction
D019253:Proto-Oncogene Proteins c-bcl-2; D012333:RNA, Messenger; D011933:Reagent Kits, Diagnostic